Canaccord's analyst, Austin Moeller, has adjusted the price target for Cibus (CBUS, Financial) from $18 to $17.50, while maintaining a Buy rating on the stock. The adjustment comes as the company has yet to generate significant commercial revenues. However, Cibus has been able to produce some quarterly income through contract research associated with its collaborative agreements for specific products and traits.
Cibus is focused on its sustainable ingredients and biofragrance product pipeline, which represents its most immediate opportunity for revenue generation. The company's efforts in these innovations are seen as a step towards eventual commercialization and increased financial performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Cibus Inc (CBUS, Financial) is $17.00 with a high estimate of $25.00 and a low estimate of $2.00. The average target implies an upside of 692.54% from the current price of $2.15. More detailed estimate data can be found on the Cibus Inc (CBUS) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Cibus Inc's (CBUS, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cibus Inc (CBUS, Financial) in one year is $7.18, suggesting a upside of 234.73% from the current price of $2.145. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cibus Inc (CBUS) Summary page.
CBUS Key Business Developments
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Cibus Inc (CBUS, Financial) has demonstrated clear validation of its commercial strategy and the transformative potential of its RTDS technology platform.
- The company has secured agreements with major rice seed companies, representing approximately 40% of accessible rice acres across North and Latin America.
- Cibus Inc (CBUS) achieved a significant milestone with field trial results for stacked, gene-edited, herbicide tolerance traits in rice.
- The company has made progress in disease resistance traits, particularly in canola, with multiple modes of action for sclerotonia resistance.
- Cibus Inc (CBUS) has advanced its bio-based fermentation bio fragrance products, anticipating commercialization agreements with consumer packaged goods partners this year.
Negative Points
- Cibus Inc (CBUS) reported a net loss of $49.4 million for the first quarter of 2025, compared to a net loss of $27 million in the year-ago period.
- The increase in net loss was primarily due to a $21 million non-cash goodwill impairment recorded in the first quarter of 2025.
- General and administrative expenses increased to $9.9 million for the first quarter of 2025, primarily due to a $3 million litigation accrual.
- The company's cash and cash equivalents are expected to fund planned operating expenses only into the third quarter of 2025.
- Cibus Inc (CBUS) is focused on significantly reducing its cash burn rate in 2025, indicating financial constraints.
